This article names the company behind Wegovy, situates it within that maker’s semaglutide and liraglutide lineup and approval dates, and contrasts the two dominant GLP-1 manufacturers. It also summarizes their shared safety warnings and explains the genetic context that precedes any protocol decision.

This article identifies the company behind Ozempic, walks through its broader GLP-1 portfolio and approval timeline, compares its molecular strategy with its main competitor, outlines the class safety profile they share, and explains the genetic context upstream of every product.